Sameul Isaly, founder of one of the world’s most well-known healthcare funds, has made two key moves on Synergy Pharmaceuticals Inc (NASDAQ:SGYP) and …
BTIG analyst Tim Chiang was out today with a research note on drug maker Synergy Pharmaceuticals Inc (NASDAQ:SGYP), noting that SGYP’s chronic idiopathic constipation (CIC) drug Trulance …
Last week, Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) excited investors with the news that its drug Trulance, a treatment approved in the indication of Chronic …
BTIG analyst Tim Chiang weighs in on Synergy Pharmaceuticals Inc (NASDAQ:SGYP), following recent data that showed strong growth in weekly prescriptions for Trulance, the company’s chronic …
In a research report released Thursday, Cantor analyst William Tanner initiated coverage on shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) with an Overweight rating and price target …
Analysts from J.P.
Believing Synergy Pharmaceuticals Inc’s (NASDAQ:SGYP) odds in the IBS-C competitive arena just got better, Rodman & Renshaw analyst Ram Selvaraju reiterates a Buy …
Canaccord analyst John Newman is out today with a research note on shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP), noting that early prescription trends are encouraging for …
During the recently-concluded Digestive Disease Week (DDW) conference held May 6-9 in Chicago, Synergy Pharmaceuticals Inc (NASDAQ:SGYP) presented additional data from the previously-announced …
Canaccord analyst John Newman weighs in with a few insights on Synergy Pharmaceuticals Inc (NASDAQ:SGYP), after Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), the main competitor for SGYP’s …
